Compound synthesis and characterization:
The synthesis of compounds 5a-b has already been reported. Because of changes in the experimental procedure and to show unpublished characterization data, we have outlined the synthesis and the characterization data for those compounds as well.
8-hydroxy-2-methyl-6-phenyl-2,7-naphthyridin-2-ium chloride (3a)
3a was synthesized from 1-methyl-3-carbamoylpyridin-1-ium chloride (0.35 g, 2 mmol) and acetophenone (0.48 g, 4 mmol) according to the general procedure published by UkawaIshikawa et al. 1 Both starting materials were dissolved in a mixture of MeOH/H 2 O (5 mL, 1:1 v/v) and treated with a KOH solution (1.5 mL, 5M). The reaction mixture was stirred for 2 h at 0 °C. Then, formic acid (8 mL) was added, and the mixture was heated for 10 min under reflux. After cooling down to room temperature, the volume of the reaction mixture was reduced by approximately 50% under reduced pressure. The reaction mixture was washed with cyclohexane. Subsequently, the pH of the aqueous layer was adjusted with KOH (5M) to a value of 11. The precipitate was separated by filtration, washed with ice-cold water, and dried under reduced pressure. The final purification step was a recrystallization from ethanol acidified with HCl. Yield: (181 mg, 33%); Appearance: yellow powder; IR absorptions (ν max /cm 
2-ethyl-8-hydroxy-6-phenyl-2,7-naphthyridin-2-ium chloride (3b)
3b was synthesized from 5a (0.57 g, 2 mmol) and acetophenone (0.48 g, 4 mmol) according to the general procedure published by Ukawa-Ishikawa et al.
1 (see 3a). Yield: (52 mg, 9%); Appearance: yellow powder; IR absorptions (ν max /cm 
2-ethyl-8-hydroxy-6-(naphthalen-2-yl)-2,7-naphthyridin-2-ium chloride (3d)
3d was synthesized from 5a (0.57 g, 2 mmol) and 1-(naphthalen-2-yl)ethan-1-one (0.68 g, 4 mmol) according to the general procedure published by Ukawa-Ishikawa et al. 1 Both starting materials were dissolved in a mixture of MeOH/H 2 O (5 mL, 1:1 v/v) and treated with a KOH solution (1.5 mL, 5M). The reaction mixture was stirred for 2 h at 0 °C. Then, formic acid (8 mL) was added, and the mixture was heated for 10 min under reflux. After cooling down to room temperature, the precipitate was separated by filtration, washed with an ice-cold mixture of H 2 O/MeOH (9:1 v/v), and dried under reduced pressure. The dry powder was dissolved in a minimal amount of a MeOH/H 2 O mixture (2:1 v/v) and the solution was acidified by the addition of HCl conc. to a pH-value of 2. This mixture was washed with cyclohexane (3x) and dried under reduced pressure. The final purification step was performed by using the semi-preparative HPLC method M1. Yield: (66 mg, 10%); Appearance: yellow powder; IR absorptions (ν max /cm 
2-benzyl-8-hydroxy-6-(naphthalen-2-yl)-2,7-naphthyridin-2-ium chloride (3e)
3e was synthesized from 5b (0.50 g, 2 mmol) and 1-(naphthalen-2-yl)ethan-1-one (0.68 g, 4 mmol) according to the general procedure published by Ukawa-Ishikawa et al. 1 Both starting materials were dissolved in a mixture of MeOH/H 2 O (5 mL, 1:1 v/v) and treated with a KOH solution (1.5 mL, 5M). The reaction mixture was stirred for 2 h at 0 °C. Then, formic acid (8 mL) was added, and the mixture was heated for 10 min under reflux. After cooling down to room temperature, the volume of the reaction mixture was reduced by approximately 50% under reduced pressure. The reaction mixture was washed with cyclohexane. Subsequently, the pH of the aqueous layer was adjusted with KOH (5M) to a value of 11. Solvents were evaporated under reduced pressure. The residue was dissolved in EtOH (10 mL) and cooled for 12 h at 4 °C. The inorganic precipitate (KCl, K(HCOO)) was separated by filtration. The ethanolic filtrate was acidified with HCl conc. to a pH-value of 2 and stored at -20 °C for 24 h. The precipitate was separated by filtration and dried under reduced pressure. The final purification step was performed by using the semi-preparative HPLC method M1. Yield: (139 mg, 17%); Appearance: yellow powder; IR absorptions (ν max /cm 
3-ethyl-5-hydroxy-11H-indeno[1,2-c][2,7]naphthyridin-3-ium chloride (3f)
3f was synthesized from 5a (0.57 g, 2 mmol) and 1-indanone (0.53 g, 4 mmol) according to the general procedure published by Ukawa-Ishikawa et al.
1 (see 3e). Yield: (11 mg, 2%); Appearance: yellow powder; IR absorptions (ν max /cm 
2-ethyl-8-hydroxy-6-(pyridin-2-yl)-2,7-naphthyridin-2-ium chloride (3h)
3h was synthesized from 5a (0.57 g, 2 mmol) and 1-(2-pyridyl)ethanone (0.48 g, 4 mmol) according to the general procedure published by Ukawa-Ishikawa et al. 1 Both starting materials were dissolved in a mixture of MeOH/H 2 O (5 mL, 1:1 v/v) and treated with a KOH solution (1.5 mL, 5M). The reaction mixture was stirred for 2 h at 0 °C. Then, formic acid (8 mL) was added, and the mixture was heated for 10 min under reflux. After cooling down to room temperature, the mixture was evaporated to dryness. The residue was recrystallized from MeOH. The precipitate was separated by filtration and dried under reduced pressure. Then, the product was recrystallized from ethanol acidified with HCl by the addition of petroleum ether. The final purification step was performed by using the semi-preparative HPLC method M1. Yield: (34 mg, 6%); Appearance: yellow powder; IR absorptions (ν max /cm 
Biological tests
Cholinesterase activity assay: Inhibition of BChE and AChE by the 8-hydroxy-2,7-naphthyridin-2-ium salts was determined using a kinetic assay in 96-well microplate format based on Ellman's reaction. 4 Two pseudo substrates, butyrylthiocholine chloride (BTCCl) and acetylthiocholine iodide (ATCI), were utilized to measure the activities of BChE and AChE, respectively. The assay conditions have been previously detailed. 5 The Ellman's method (1961) uses 5,5'-dithiobis(2-nitro-benzoic acid) (DTNB, Ellman's reagent) which forms a colored anion (5-thio-2-nitro-benzoic acid) after reacting with the product of cholinesterase reaction. Spontaneous and enzymatic hydrolysis was measured spectrophotometrically at λ = 412 nm using Varioskan Flash multimode plate reader (Thermo Fisher Scientific, Finland). Compounds were tested at 10 µM in the primary screening. Compounds that displayed more than 75% inhibition against any of the target enzymes at 10 µM were further characterized with dose-response experiments. These trials were performed against a wide concentration range (8 replicates per concentration, with 2 biological replicates). IC 50 values were calculated with Prism program (version 5 for Windows) using a non-linear regression (sigmoidal fitting, four parameters with variable slope). Physostigmine (in methanol, final concentration of 10 µM) was used as a positive control to assess the assay accuracy during the screening trials, while DMSO:buffer Tris-HCl 50 mM pH 8 was used as solvent control. Final concentration of DMSO in the assay did not exceed 0.05%. As blank controls for our 8-hydroxy-2,7-naphthyridin-2-ium salts we detected their absorption before the enzymatic reaction was started. The enzymatic reaction was started with the addition of the enzyme. Enzymes used and their final concentrations were: equine BChE (EC 3.1.1.8, from equine serum, Sigma-Aldrich, USA) 0.350 U/ml; electric eel AChE (EC 3.1.1.7, from Electric eel, Sigma-Aldrich, USA) 0.224 U/ml. Reactions took place at room temperature (25 °C).
pK a determination via UV-Vis spectroscopy
To determine the pK a value of the 8-hydroxy-2,7-naphthyridin-2-ium salts, by the example of compound 3a, we recorded absorption spectra (λ = 300 -500 nm) at different pH values (pH = 2.3, 7.3, 8.0, 8.5, 9.2, 12.3) at a compound concentration of 52 µM (Fig S1) . We used the spectrometer Lambda 10 from PerkinElmer for absorption detection. The physical basics for S8 our pK a determination via UV-Vis spectroscopy is the Beer-Lambert law (Eq. 1) and the Henderson-Hasselbalch equation (Eq.2). 
Molecular docking
Computational Methods: The crystal structures of donepezil in complex with Torpedo californica (Tc) AChE (PDB-ID: 1EVE solved at 2.5 Å), 6 electrophorus electricus (Ee) AChE (PDB-ID: 1EEA), 7 and human BChE in complex with benzyl pyridinium-4-methyltrichloroacetimidate (PDB-ID: 4B0O solved at 2.35 Å) 8 were taken from the Protein Data Bank. 9 The crystal structure of EeAChE has been solved only in the apo form and at low resolution (4.2 Å). Since the sequence identity of the binding pocket of TcAChE and EeAChE is 100% as well as the structural overlay of both pockets showed a small deviation (0.30 Å) we took the protein from the TcAChE-donepezil structure for docking. In case of BuChE there is no crystal structure of the horse serum enzyme available, therefore we used the human enzyme which has been crystallized with a benzylpyridinium salt (PDB ID 4B0O) that shows similarity to the novel inhibitors developed in this work. Human and horse serum enzyme show an overall sequence identity of 90% and of 95% in the inhibitor binding pocket. Only one substitution is observed within the inhibitor binding pocket, Pro285 is mutated to Leu285 in horse serum BuChE. Both are hydrophobic residues with comparable side chain location. We generated a homology model of horse serum BuChE using the human enzyme using program MODELLER. The RMSD value of the superimposed binding pocket atoms was 0.1 Å indicating the nearly identical binding pockets. Redocking of the inhibitor cocrystallized in PDB ID 4B0O gave the same results as observed for the human BuChE. For the docking study, the heteroatoms and water molecules (excluded the water molecule bound at the binding site) were removed and hydrogen atoms were added to the protein structures by using the program MOE 2012.10. 10 All protein and ligand structures were built and protonated using the protonate 3D protocol and energy minimized using the MMFF94 force field in MOE 2012.10. For the 8-hydroxy-2,7-naphthyridin-2-ium salts the pyridone (9) and hydroxypyridine (3) tautormers were generated. Docking of the ligands was carried out using Glide SP Schrodinger 2014u2 with default settings. 11 A sphere of 16 Å around the co-crystallized inhibitor was defined as the binding site for the ligand docking and 25 confirmations were generated for each ligand. Four conserved water molecules located in the BChE and five conserved water molecules in TcAChE binding pocket were considered for the inhibitor docking. The docking results were analyzed using MOE 2012.10. The protein-inhibitor complexes were finally minimized in MOE using the AMBER12_EHT force field and the GB/SA solvation model using default values. The protocol was able to reproduce the crystal structure of donepezil with 0.44 Å (PDB ID 1EVE) and the structure of benzyl pyridinium-4 methyltrichloroacetimidate with 0.88 Å (PDB ID 4B0O) by using the top-scored inhibitor pose. Fig. S1 . Absorption spectra of 3a at different pH-values. Table   Table S1 : Excitation and emission maxima ( abs max and  em max ), relative fluorescence intensity (FI) and fluorescence quantum yield ( F ) of compound 3a-h. Measurements were performed using aqueous Tris buffer (25 mM, pH = 8) at room temperature. Relative fluorescence intensity was determined at a compound concentration of 15 nM.
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Supplementary NMR spectra 1 H NMR (400 MHz, DMSO-D 6 ) for 8-hydroxy-2-methyl-6-phenyl-2,7-naphthyridin-2-ium chloride (3a):
13 C NMR (100 MHz, DMSO-D 6 ) for 8-hydroxy-2-methyl-6-phenyl-2,7-naphthyridin-2-ium chloride (3a): S16 1 H NMR (400 MHz, DMSO-D 6 ) for 2-ethyl-8-hydroxy-6-phenyl-2,7-naphthyridin-2-ium chloride (3b):
13 C NMR (100 MHz, DMSO-D 6 ) for 2-ethyl-8-hydroxy-6-phenyl-2,7-naphthyridin-2-ium chloride (3b): S17 1 H NMR (400 MHz, DMSO-D 6 ) for 2-benzyl-8-hydroxy-6-phenyl-2,7-naphthyridin-2-ium chloride (3c):
13 C NMR (100 MHz, DMSO-D 6 ) for 2-benzyl-8-hydroxy-6-phenyl-2,7-naphthyridin-2-ium chloride (3c): S18 1 H NMR (400 MHz, CD 3 OD) for 2-ethyl-8-hydroxy-6-(naphthalen-2-yl)-2,7-naphthyridin-2-ium chloride (3d):
13 C NMR (400 MHz, DMSO-D 6 ) for 2-ethyl-8-hydroxy-6-(naphthalen-2-yl)-2,7-naphthyridin-2-ium chloride (3d): S19 1 H NMR (400 MHz, DMSO-D 6 ) for 2-benzyl-8-hydroxy-6-(naphthalen-2-yl)-2,7-naphthyridin-2-ium chloride (3e):
13 C NMR (400 MHz, DMSO-D 6 ) for 2-benzyl-8-hydroxy-6-(naphthalen-2-yl)-2,7-naphthyridin-2-ium chloride (3e): 
